These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16185904)

  • 21. Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy.
    Lee AG; Newman NJ
    Am J Ophthalmol; 2005 Oct; 140(4):707-8. PubMed ID: 16226524
    [No Abstract]   [Full Text] [Related]  

  • 22. Backbone 1H, 13C, and 15N resonance assignment of the 46 kDa dimeric GAF A domain of phosphodiesterase 5.
    Sekharan MR; Rajagopal P; Klevit RE
    J Biomol NMR; 2005 Sep; 33(1):75. PubMed ID: 16222566
    [No Abstract]   [Full Text] [Related]  

  • 23. Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?
    Oliver JJ
    Int J Clin Pract; 2006 Sep; 60(9):1026-7. PubMed ID: 16939541
    [No Abstract]   [Full Text] [Related]  

  • 24. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Lau DH; Thompson CS; Morgan RJ; Mumtaz FH; Mikhailidis DP
    BJU Int; 2005 Dec; 96(9):1424. PubMed ID: 16287475
    [No Abstract]   [Full Text] [Related]  

  • 25. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JNJ-10280205 and JNJ-10287069: Novel PDE5 inhibitors as clinical candidates for erectile dysfunction.
    Qiu Y; Bhattacharjee S; Kraft P; Mathew John T; Haynes-Johnson D; Jiang W; Sui Z; Lundeen S
    Int J Impot Res; 2006; 18(5):477-83. PubMed ID: 16528290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction.
    Francis SH; Corbin JD
    Urol Clin North Am; 2005 Nov; 32(4):419-29, vi. PubMed ID: 16291034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cluster analysis and two-dimensional quantitative structure-activity relationship (2D-QSAR) of Pseudomonas aeruginosa deacetylase LpxC inhibitors.
    Kadam RU; Roy N
    Bioorg Med Chem Lett; 2006 Oct; 16(19):5136-43. PubMed ID: 16879960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationships of N-acyl pyrroloquinolone PDE-5 inhibitors.
    Lanter JC; Sui Z; Macielag MJ; Fiordeliso JJ; Jiang W; Qiu Y; Bhattacharjee S; Kraft P; John TM; Haynes-Johnson D; Craig E; Clancy J
    J Med Chem; 2004 Jan; 47(3):656-62. PubMed ID: 14736245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [7 years PDE-5 inhibitor for therapy of erection disorders].
    Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
    [No Abstract]   [Full Text] [Related]  

  • 31. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
    Schermuly RT; Pullamsetti SS; Kwapiszewska G; Dumitrascu R; Tian X; Weissmann N; Ghofrani HA; Kaulen C; Dunkern T; Schudt C; Voswinckel R; Zhou J; Samidurai A; Klepetko W; Paddenberg R; Kummer W; Seeger W; Grimminger F
    Circulation; 2007 May; 115(17):2331-9. PubMed ID: 17438150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of phosphodiesterase 5 selectively reverses nitrate tolerance in the venous circulation.
    MacPherson JD; Gillespie TD; Dunkerley HA; Maurice DH; Bennett BM
    J Pharmacol Exp Ther; 2006 Apr; 317(1):188-95. PubMed ID: 16330494
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New antithrombotics with an indazole structure.
    Yildiz AK; Rehse K; Stasch JP; Bischoff E
    Arch Pharm (Weinheim); 2004 Jun; 337(6):311-6. PubMed ID: 15188220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The CYP2C9 genotype does not influence sildenafil pharmacokinetics in healthy volunteers.
    Jetter A; Lazar A; Schömig E; Fuhr U; Kinzig-Schippers M; Sörgel F
    Clin Pharmacol Ther; 2005 Oct; 78(4):441-3. PubMed ID: 16198665
    [No Abstract]   [Full Text] [Related]  

  • 35. A high-throughput assay for cyclic nucleotide phosphodiesterases.
    Schilling RJ; Morgan DR; Kilpatrick BF
    Anal Biochem; 1994 Jan; 216(1):154-8. PubMed ID: 8135346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
    Hotston M; Shukla N; Bloor J; Persad R; Jeremy JY
    BJU Int; 2006 Dec; 98(6):1331-2. PubMed ID: 17125493
    [No Abstract]   [Full Text] [Related]  

  • 37. Salvage techniques for phosphodiesterase 5 inhibitor therapy: purposeful but how much?
    Burnett AL
    Eur Urol; 2006 Jul; 50(1):29-30. PubMed ID: 16567036
    [No Abstract]   [Full Text] [Related]  

  • 38. Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens.
    Seftel AD
    J Urol; 2005 Sep; 174(3):1043. PubMed ID: 16094045
    [No Abstract]   [Full Text] [Related]  

  • 39. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors.
    Jackson G
    Am J Cardiol; 2005 Dec; 96(12B):32M-36M. PubMed ID: 16387564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphodiesterase 5 mechanisms and therapeutic applications.
    Burnett AL
    Am J Cardiol; 2005 Dec; 96(12B):29M-31M. PubMed ID: 16387563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.